-Germline and somatic genetic changes in breast cancer.
-Identification and management of individuals and families with hereditary cancer risk.
-Communication of cancer risk information to individuals and families.
-Breast cancer prevention.
-Optimizing management of early breast cancer.
-Treatment of metastatic breast cancer
Clinically, Dr. Marcom works as a medical oncologist in the multidisciplinary breast cancer clinic. He participates in clinical trials investigating new chemotherapeutic and biologic treatments. In addition, he is developing a new high risk, familial cancer clinic. This clinic will see patients and families thought to be at high risk of developing malignancies, and will interface with the forming Cancer Genetics Network. Patients and families will be counseled about their cancer risk, and identified for studying issues related to cancer genetics: determining penetrance of identified gene mutations, determining factors modifying genetic risk, prevention studies, etc. Finally, he also plans to be involved in clinical evaluation of drugs for treating breast cancer.
Areas of developing expertise include cell cycle alterations in malignancy, breast cancer, and hereditary cancer genetics.
Breast cancer, cell cycle, genetics, familial cancer, prognostic factors, angiogenesis
Education and Training
- Fellow in Hematology-Oncology, Medicine, Duke University, 1992 - 1995
- Medical Resident, Medicine, Duke University, 1989 - 1992
- M.D., Baylor University, 1989
- TBCRC 041 Randomized Phase II Trial to Evaluate Alisertib Alone or Combined with Fulvestrant in Women with Advanced, Hormone-Receptor Positive (HR+) Breast Cancer
- TBCRC48 A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded"
- Postdoctoral Training in Genomic Medicine Research
- Targeting Dormant Breast Cancer Micrometastases to Prevent Disease Relapse
- Innocrin VT-464
- Can contrast dynamics in breast MRI predict genomic intra-tumor heterogeneity
- A randomized phase II study of adjuvant Trastuzumab emtansine (T-DM1) vs Paclitaxel
- Targeting precursor neural (N)-cadherin to eliminate chemotherapy-resistant triple-negative breast tumor cells
- Kastan Gray Foundation Project
- A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS
- Deep learning for prognostication in breast cancer
- Translational Breast Cancer Research Consortium 2018 Infrastructure (BCRF)
- Translational Breast Cancer Research Consortium 2018 Infrastructure - SGK
- Translational Breast Cancer Research Consortium-2017 Komen Foundation SGK
- A RANDOMIZED PHASE II STUDY OF PREOPERATIVE CISPLATIN VS PACLITAXEL IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER